hVIVO (LON:HVO) Stock Price Down 4.1% – Should You Sell?

hVIVO plc (LON:HVO)’s share price was down 4.1% during trading on Tuesday . The company traded as low as GBX 6.80 ($0.09) and last traded at GBX 7 ($0.09). Approximately 4,704,116 shares were traded during mid-day trading, an increase of 61% from the average daily volume of 2,922,295 shares. The stock had previously closed at GBX 7.30 ($0.10).

Wall Street Analysts Forecast Growth

Several research analysts have issued reports on the stock. Peel Hunt restated an “add” rating and set a GBX 21 price target on shares of hVIVO in a report on Tuesday, July 29th. Shore Capital decreased their price target on hVIVO from GBX 35 to GBX 25 and set a “buy” rating for the company in a report on Tuesday, September 23rd. Two research analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, the company has an average rating of “Buy” and a consensus target price of GBX 23.

hVIVO Trading Down 3.1%

The company has a debt-to-equity ratio of 33.86, a current ratio of 1.61 and a quick ratio of 1.16. The firm has a fifty day simple moving average of GBX 9.56 and a 200-day simple moving average of GBX 12.24. The firm has a market cap of £45.94 million, a P/E ratio of 868.18 and a beta of 0.97.

hVIVO (LON:HVO) last issued its earnings results on Tuesday, September 23rd. The company reported GBX (0.29) earnings per share (EPS) for the quarter. hVIVO had a return on equity of 47.93% and a net margin of 25.96%. On average, equities research analysts expect that hVIVO plc will post 1.5492958 earnings per share for the current year.

hVIVO Company Profile

hVIVO plc operates as a pharmaceutical service and contract research company. The company is involved in testing vaccines and antivirals using human challenge clinical trials. It provides services to big pharma, biotech, government, and public health organizations. The company has a portfolio of human challenge study models for conditions, such as RSV, flu, human rhinovirus, asthma, malaria, cough, and COPD, as well as developing COVID-19 human challenge study model.